Difficulty: Medium
Average Score: 69%
Practice
A 57-year-old man with a seizure disorder takes anti-epileptic medications. His physician would like to use a medicine that is metabolized only by the CYP1A2 receptor. Which of the following agents would be preferred?
Correct answer
C
Rationale
In this scenario, the preferred agent for the 57-year-old man with a seizure disorder who takes anti-epileptic medications and needs a drug metabolized only by the CYP1A2 receptor is Felbamate (Option C). Felbamate is the preferred choice because it is primarily metabolized by the CYP1A2 enzyme, ensuring minimal drug interactions and optimal therapeutic effect in this patient population.
Carbamazepine (Option A) is metabolized by CYP3A4 and CYP2C19 enzymes, not CYP1A2. Divalproex (Option B) is metabolized by various enzymes including CYP2C9 and CYP2C19, not CYP1A2. Phenobarbital (Option D) is mainly metabolized by CYP2C19 and CYP2C9, not CYP1A2.
Educationally, understanding the metabolic pathways of drugs is crucial for healthcare professionals to make informed decisions about drug selection, dosing, and potential drug interactions in patients. This knowledge helps in providing safe and effective care to patients with complex medical conditions like seizure disorders. It also highlights the importance of individualized treatment plans based on the patient's unique characteristics to optimize therapeutic outcomes and minimize adverse effects.
Carbamazepine (Option A) is metabolized by CYP3A4 and CYP2C19 enzymes, not CYP1A2. Divalproex (Option B) is metabolized by various enzymes including CYP2C9 and CYP2C19, not CYP1A2. Phenobarbital (Option D) is mainly metabolized by CYP2C19 and CYP2C9, not CYP1A2.
Educationally, understanding the metabolic pathways of drugs is crucial for healthcare professionals to make informed decisions about drug selection, dosing, and potential drug interactions in patients. This knowledge helps in providing safe and effective care to patients with complex medical conditions like seizure disorders. It also highlights the importance of individualized treatment plans based on the patient's unique characteristics to optimize therapeutic outcomes and minimize adverse effects.